Quick Ebola vax development could assist with future outbreaks; GSK touts 'major' Synflorix label expansion;

> The rapid development of Merck's ($MRK) Ebola vaccine--which this week was reported to protect 100% of patients in a Phase III trial--could provide a model for addressing future outbreaks. More

> The Committee for Medicinal Products for Human Use (CHMP) granted GlaxoSmithKline's ($GSK) Synflorix a label expansion to include effectiveness data for protection against invasive pneumococcal disease and pneumonia and acute otitis media caused by the pneumococcus bacterium. Release

> BiondVax ($BVXV) reported that its universal flu vaccine candidate, administered in a Phase II trial 3 years ago, provided patients with increased immunogenicity against influenza strains that didn't exist at the time of the study. Release

And Finally... A 15-year-old developed a vapor-compression refrigeration system requiring minimal power to transport vaccines. More

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.